Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017

Published: Jul, 2017 | Pages: 202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 20

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 11, 22, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 23
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 31
Akcea Therapeutics Inc 31
Allergan Plc 31
Ardelyx Inc 32
AstraZeneca Plc 32
Betagenon AB 33
Bird Rock Bio Inc 33
Boehringer Ingelheim GmbH 34
Can-Fite BioPharma Ltd 34
Cerenis Therapeutics Holding SA 35
CJ HealthCare Corp 35
Conatus Pharmaceuticals Inc 36
Corcept Therapeutics Inc 36
CymaBay Therapeutics Inc 37
Daewoong Pharmaceutical Co Ltd 37
Dimerix Bioscience Pty Ltd 38
Dr. Falk Pharma GmbH 38
DURECT Corp 39
Enanta Pharmaceuticals Inc 39
Eternygen GmbH 40
Galmed Pharmaceuticals Ltd 40
Gemphire Therapeutics Inc 41
Genfit SA 41
Gilead Sciences Inc 42
Huons Co Ltd 42
Immuron Ltd 43
Kyorin Pharmaceutical Co Ltd 43
Matinas BioPharma Holdings Inc 44
Metacrine Inc 44
Miyarisan Pharmaceutical Company Ltd 45
Nordic Bioscience A/S 45
NovaTarg Therapeutics Inc 46
Ocera Therapeutics Inc 46
Pfizer Inc 47
Renova Therapeutics Inc 47
Sancilio & Company Inc 48
Shenzhen HighTide Biopharmaceutical Ltd 48
TaiwanJ Pharmaceuticals Co Ltd 49
TCM Biotech International Corp 49
Zydus Cadila Healthcare Ltd 50
Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 51
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 51
(leucine + PDE5 Inhibitor) - Drug Profile 53
AC-261066 - Drug Profile 54
AF-102 - Drug Profile 55
AKCEA-ANGPTL3LRx - Drug Profile 56
Aramchol - Drug Profile 58
ARI-3037MO - Drug Profile 64
AZD-4076 - Drug Profile 66
C-10 - Drug Profile 68
CBM-588 - Drug Profile 70
cenicriviroc mesylate - Drug Profile 72
CER-209 - Drug Profile 80
CJ-14199 - Drug Profile 82
CORT-118335 - Drug Profile 83
dabigatran etexilate mesylate - Drug Profile 84
DMX-300 - Drug Profile 86
Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 87
DUR-928 - Drug Profile 88
DWP-10292 - Drug Profile 93
EDP-305 - Drug Profile 94
elafibranor - Drug Profile 96
emricasan - Drug Profile 105
FGF-1 Program - Drug Profile 113
FLB-12 - Drug Profile 114
gemcabene calcium - Drug Profile 115
GS-9674 - Drug Profile 120
HTD-1801 - Drug Profile 123
HU-002 - Drug Profile 124
IMM-124E - Drug Profile 125
KBP-089 - Drug Profile 128
KM-2702 - Drug Profile 129
liothyronine sodium - Drug Profile 130
MAT-8800 - Drug Profile 131
MN-002 - Drug Profile 132
naltrexone hydrochloride - Drug Profile 134
Namacizumab - Drug Profile 136
namodenoson - Drug Profile 137
ND-630 - Drug Profile 143
NLM-0100 - Drug Profile 145
norursodeoxycholic acid - Drug Profile 146
O-304 - Drug Profile 147
oltipraz - Drug Profile 149
ornithine phenylacetate - Drug Profile 150
PF-06835919 - Drug Profile 157
RDX-023 - Drug Profile 158
RT-200 - Drug Profile 159
RT-210 - Drug Profile 160
saroglitazar - Drug Profile 161
SC-410 - Drug Profile 164
seladelpar lysine - Drug Profile 165
selonsertib - Drug Profile 169
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 172
Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 173
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 174
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 175
Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 176
TCM-606F - Drug Profile 177
tipelukast - Drug Profile 178
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 183
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 184
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Akcea Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ardelyx Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CJ HealthCare Corp, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Nordic Bioscience A/S, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ocera Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2017